Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
| Date | Quarter | Revenue Forecast | Actual Revenue | Reported EPS | Consensus EPS | Beat/Miss |
|---|---|---|---|---|---|---|
| 02/04/2026 | Q4 | $5.3B | -- | -- | $0.78 | -- |
| 10/22/2025 | Q3 | $5B | $5.1B | $0.50 | $0.71 | -$0.21 |
| 07/23/2025 | Q2 | $4.9B | $5.1B | $0.53 | $0.73 | -$0.19 |
| 04/23/2025 | Q1 | $4.6B | $4.7B | $0.45 | $0.67 | -$0.22 |
| 02/05/2025 | Q4 | $4.4B | $4.6B | $0.38 | $0.66 | -$0.28 |
| 10/23/2024 | Q3 | $4B | $4.2B | $0.32 | $0.59 | -$0.27 |
| 07/24/2024 | Q2 | $4B | $4.1B | $0.22 | $0.58 | -$0.36 |
| 04/24/2024 | Q1 | $3.7B | $3.9B | $0.33 | $0.51 | -$0.18 |
| 01/31/2024 | Q4 | $3.6B | $3.7B | $0.34 | $0.51 | -$0.17 |
| 10/26/2023 | Q3 | $3.5B | $3.5B | $0.34 | $0.48 | -$0.14 |
| 07/27/2023 | Q2 | -- | $3.6B | $0.18 | -- | -- |
| 04/26/2023 | Q1 | -- | $3.4B | $0.21 | -- | -- |
| 02/01/2023 | Q4 | -- | $3.2B | $0.09 | -- | -- |
| 10/26/2022 | Q3 | -- | $3.2B | $0.12 | -- | -- |
| 07/27/2022 | Q2 | -- | $3.2B | $0.17 | -- | -- |
| 04/27/2022 | Q1 | -- | $3B | $0.07 | -- | -- |
| 02/02/2022 | Q4 | -- | $3.1B | $0.06 | -- | -- |
| 10/27/2021 | Q3 | -- | $2.9B | $0.28 | -- | -- |
| 07/27/2021 | Q2 | -- | $3.1B | $0.12 | -- | -- |
| 04/28/2021 | Q1 | -- | $2.8B | $0.23 | -- | -- |
| 02/03/2021 | Q4 | -- | $2.7B | $0.10 | -- | -- |
| 10/28/2020 | Q3 | -- | $2.7B | -$0.12 | -- | -- |
| 07/29/2020 | Q2 | -- | $2B | -$0.11 | -- | -- |
| 04/29/2020 | Q1 | -- | $2.5B | $0.01 | -- | -- |
| 01/24/2020 | Q4 | -- | $2.9B | $2.83 | -- | -- |
| 10/23/2019 | Q3 | -- | $2.7B | $0.09 | -- | -- |
| 07/24/2019 | Q2 | -- | $2.6B | $0.11 | -- | -- |
| 04/24/2019 | Q1 | -- | $2.5B | $0.30 | -- | -- |
| 02/06/2019 | Q4 | -- | $2.6B | $0.27 | -- | -- |
| 10/24/2018 | Q3 | -- | $2.4B | $0.31 | -- | -- |
| 07/25/2018 | Q2 | -- | $2.5B | $0.40 | -- | -- |
| 04/25/2018 | Q1 | -- | $2.4B | $0.21 | -- | -- |
| 02/01/2018 | Q4 | -- | $2.4B | -$0.45 | -- | -- |
| 10/26/2017 | Q3 | -- | $2.2B | $0.20 | -- | -- |
| 07/27/2017 | Q2 | -- | $2.3B | $0.11 | -- | -- |
| 04/27/2017 | Q1 | -- | $2.2B | $0.21 | -- | -- |
| 02/02/2017 | Q4 | -- | $2.2B | $0.09 | -- | -- |
| 10/26/2016 | Q3 | -- | $2.1B | $0.17 | -- | -- |
| 07/28/2016 | Q2 | -- | $2.1B | -$0.15 | -- | -- |
| 04/27/2016 | Q1 | -- | $2B | $0.15 | -- | -- |
| 02/04/2016 | Q4 | -- | $2B | -$0.11 | -- | -- |
Boston Scientific Corp. reported $5.1B worth of top line sales in its most recent quarter.
Boston Scientific Corp. announced earnings per share of $0.50 which represents a miss of analyst forecast a $0.71 per share.
Boston Scientific Corp. reported $3.3B that represents $2.21 per share over the last quarter.
Boston Scientific Corp.'s earnings are forecast to grow from $1.25 per share to $2.46 per share next year representing an increase of 143.28%.
Boston Scientific Corp.'s next earnings date is February 4, 2026.
Signup to receive the latest stock alerts
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Market Cap: $4.6T
P/E Ratio: 64x
Market Cap: $4T
P/E Ratio: 37x
Market Cap: $3.8T
P/E Ratio: 39x
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.